Storia in 3 fonti

Vertex Pops As A Key Rival Plummets 90%

Vertex stock surged Monday after its competitor, Sionna, missed the mark for its highly anticipated cystic fibrosis treatment.

Raccontata da

biopharmadive.com

investors.com

endpoints.news

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo3 g fa

Vertex Pops As A Key Rival Plummets 90%

Vertex stock surged Monday after its competitor, Sionna, missed the mark for its highly anticipated cystic fibrosis treatment.

originale

endpoints.news3 g fa

Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex

Sionna Therapeutics’ shares fell more than 90% after reporting that its lead asset failed an early study and it is no longer advancing the experimental treatment going forward. Vertex's shares hit an all-time high at…

Leggi questa versione → originale

Timeline cronologica

lunedì 10 agosto 2026·biopharmadive.com
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
lunedì 10 agosto 2026·investors.com
Vertex Pops As A Key Rival Plummets 90%
Vertex stock surged Monday after its competitor, Sionna, missed the mark for its highly anticipated cystic fibrosis treatment.

Vertex Pops As A Key Rival Plummets 90%

Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex

Timeline cronologica

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Vertex Pops As A Key Rival Plummets 90%

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex